Qtern (Dapagliflozin/Saxagliptin HCl) Patent Expiration, LOE Window & CMS Spending
Qtern (Dapagliflozin/Saxagliptin HCl) by AstraZeneca: FDA Orange Book core substance LOE 2030-06-16, 2 AB generics, $1.7M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N209091 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2030-06-16 |
| Last Listed Patent or Exclusivity Date | 2030-06-16 |
| Orange Book Patents (*PED Extensions) | 12 patents (6 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $1.7M |
| 2024 Medicare Part D Spend | $1.6M |
| 2024 Medicaid Spend | $86K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.